22:14 , Jun 14, 2019 |  BioCentury  |  Emerging Company Profile

Sherlock: Leveraging CRISPR, synthetic biology for diagnostics

By taking advantage of two hot technologies, Sherlock is developing a pair of molecular diagnostics that can be used alone or together to rapidly and accurately detect disease in a wide variety of applications. Sherlock...
21:48 , Jun 6, 2019 |  BC Innovations  |  Translation in Brief

CRISPR pioneer Zhang describes new technique to insert genes

Feng Zhang's latest study brings the gene editing field one step closer to correcting and replacing, rather than just disrupting, target genes. The challenge now will be translating the technique from prokaryotic cells to eukaryotic...
00:45 , Jun 5, 2019 |  BC Innovations  |  Translation in Brief

New Therapeutic Targets and Biomarkers: May 2019

New Therapeutic Targets and Biomarkers: May 2019 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database during May. Therapeutic targets are defined as any protein, gene or other molecule...
14:58 , May 30, 2019 |  BioCentury  |  Emerging Company Profile

Thrive’s quest to bring multicancer liquid biopsy test into routine clinical use

With Third Rock leading the way in a $110 million series A, newly launched Thrive is banking that a multi-analyte approach to liquid biopsy could give it an edge in creating a test that is...
21:58 , May 28, 2019 |  BC Innovations  |  Translation in Brief

Liu’s new strategy could make gene editing insertions more precise

The latest study from CRISPR veteran David Liu describes a new tweak to the gene editing machinery that could better position it to correct, rather than just disrupt, gene targets. Using CRISPR to disrupt a...
23:44 , May 23, 2019 |  BC Extra  |  Company News

May 23 Company Quick Takes: Chiesi gains Raxone rights; plus WuXi Vaccines, a Zika first and more

Chiesi gains rights to Santhera's Raxone for LHON  Santhera Pharmaceuticals Holding AG (SIX:SANN) granted Chiesi Farmaceutici S.p.A. (Parma, Italy) exclusive, worldwide rights outside of the U.S. and Canada to Raxone idebenone for Leber hereditary optic...
23:18 , May 22, 2019 |  BC Extra  |  Politics & Policy

Launch of germline gene editing commission provides first look at priorities, representatives

An international commission tasked with creating a framework for assessing potential clinical applications of human germline genome editing launched Wednesday, providing the first details of the composition of its membership and oversight board, timeline and...
15:32 , May 21, 2019 |  BC Extra  |  Company News

Merck bets on HIF2As with Peloton takeout ahead of planned listing

Days before Peloton was to price an IPO that would fund Phase III testing of its HIF2A program to treat kidney cancer, the biotech has elected instead to take a buyout offer from Merck &...
14:20 , May 14, 2019 |  BC Innovations  |  Distillery Therapeutics

GSK3A inhibition restores asparaginase sensitivity in resistant ALL, AML

DISEASE CATEGORY: Cancer INDICATION: Acute lymphoblastic leukemia (ALL); acute myelogenous leukemia (AML) Cell culture and mouse studies suggest inhibiting GSK3A could help treat asparaginase-resistant T cell and B cell ALL and AML. In a T...
09:59 , May 7, 2019 |  BC Innovations  |  Emerging Company Profile

Verve turns CRISPR against cardiovascular disease

Most CRISPR companies are targeting rare genetic disorders, but Verve is breaking from the trend with gene editing therapies for coronary artery disease that could have fewer side effects, greater efficacy and better compliance than...